Content deleted Content added
209.59.105.146 (talk) No edit summary |
Added new vector image |
||
Line 1: | Line 1: | ||
{{drugbox | |
{{drugbox | |
||
|Image = Aminoglutethimide. |
|Image = Aminoglutethimide.svg |
||
|IUPAC_name =3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione |
|IUPAC_name =3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione |
||
|CAS_number =125-84-8 |
|CAS_number =125-84-8 |
Revision as of 02:23, 3 January 2008
Clinical data | |
---|---|
Pregnancy category | |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Bioavailability | >95% |
Metabolism | Hepatic |
Elimination half-life | 12.5 ± 1.6 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.325 |
Chemical and physical data | |
Formula | C13H16N2O2 |
Molar mass | 232.278 g/mol g·mol−1 |
Aminoglutethimide blocks the conversion of cholesterol to pregnenolone by inhibiting the enzyme desmolase, thus inhibits synthesis of all hormonally active steroids. It can be used in conjunction with other drugs for treatment of steroid-producing adrenocortical cancer.
Its major side effects are liver toxicity, inhibition of cortisol in the human body, and it may also cause hypothyroidism. Since cortisol helps break down muscle, aminoglutethimide is used by bodybuilders in a steroid cycle.
It is still used to suppress corticosteroid production in Cushing's Syndrome.
See also
External links